Crescent Biopharma (CBIO) Enterprise Value Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.77% |
| Dec 31, 2025 | -64.53% |
| Sep 30, 2025 | -37.20% |
| Mar 31, 2025 | 33.57% |
| Dec 31, 2024 | 27.24% |
| Sep 30, 2024 | 47.92% |
| Jun 30, 2024 | 42.67% |
| Mar 31, 2024 | 38.19% |
| Dec 31, 2023 | 32.69% |
| Sep 30, 2023 | 29.81% |
| Mar 31, 2023 | 25.12% |
| Dec 31, 2022 | 32.86% |
| Sep 30, 2022 | 32.91% |
| Jun 30, 2022 | 31.11% |
| Mar 31, 2022 | 26.86% |
| Dec 31, 2021 | 24.52% |
| Sep 30, 2021 | 22.60% |
| Jun 30, 2021 | 19.69% |
| Mar 31, 2021 | 18.27% |
| Dec 31, 2020 | -3.41% |
| Sep 30, 2020 | -8.17% |
| Mar 31, 2020 | -64.79% |
| Dec 31, 2019 | -58.07% |
| Sep 30, 2019 | -55.69% |
| Jun 30, 2019 | -51.38% |
| Mar 31, 2019 | -71.40% |
| Dec 31, 2018 | -64.90% |
| Sep 30, 2018 | -59.90% |
| Jun 30, 2018 | -78.64% |
| Mar 31, 2018 | -73.35% |
| Dec 31, 2017 | -30.93% |
| Sep 30, 2017 | -22.53% |
| Jun 30, 2017 | -21.63% |
| Mar 31, 2017 | 15.32% |
| Dec 31, 2016 | -158.76% |
| Sep 30, 2016 | -80.58% |
| Jun 30, 2016 | -70.14% |
| Mar 31, 2016 | -42.26% |